March 28th 2024
Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Study advises that all young acne patients be screened for depression
December 5th 2006Auckland, New Zealand ? A University of Auckland study conducted by researchers who have studied the link between teens with acne and those who have suicidal thoughts suggests that all young people seeking treatment for acne should be screened for depression.
Are your winter-rosy cheeks a little too rosy?
December 1st 2006An inflammatory skin disease shared by the likes of Princess Di, Bill Clinton and W.C.Fields, rosacea can start innocently with a flush on your cheeks that seems to last just a little too long. You may notice it after working out, eating spicy foods or even sipping a glass of red wine.
FDA Goals: Agency hopes to streamline risk communication, device review
December 1st 2006National report - The Food and Drug Administration's plans for 2007 and beyond include greater attention to postmarket risks and more timely reviews of medical devices, including those used for plastic and reconstructive surgery, spokesmen say.
Physician responds to Chester Valley concerns
December 1st 2006EDITOR'S NOTE: Dr. Leon Kircik is replying to a clarification from Chester Valley Pharmaceuticals that ran in our November issue on an article in the October issue, "Vehicles often drive treatment of difficult ailments." Atopiclair is Chester Valley Pharmaceutical's product. While Dr. Kircik was not the author of the article (he was interviewed by Senior Staff Correspondent John Jesitus) he did see the article before it went to press for his approval, as is Dermatology Times' standard practice with clinical articles.
Long-suffering rosacea patient asks, 'Doctors, please listen to your patients'
December 1st 2006In his Guest Commentary "Managing rosacea; practitioners discuss trends" (September 2006), Dr. William Baum presents his findings after moderating advisory panels across the country consisting of specialists talking about the many facets of rosacea.
New study shows betamethasone's effectiveness in treating psoriasis
November 7th 2006Bochum, Germany-Results of a recent study conducted at Ruhr University here suggest that the corticosteroid betamethasone is more effective for treatment of intertriginous psoriasis than is pimecrolimus or calcipotriol.
Indoor tanning restrictions top priority for AAD
November 1st 2006On behalf of the American Academy of Dermatology, I would like to respond to a letter to the editor from Michael Franzblau, M.D., regarding the Academy's efforts to restrict access to indoor tanning equipment. ("Cannot fathom AAD/AADA indifference toward indoor tanning regs," September, 2006). The letter's criticisms are not supported by the facts, and I appreciate the opportunity to set the record straight.